Research Analysts Issue Forecasts for Biogen Q3 Earnings

Biogen Inc. (NASDAQ:BIIB) – Research analysts at William Blair issued their Q3 2025 EPS estimates for shares of Biogen in a research report issued to clients and investors on Tuesday, July 15th. William Blair analyst M. Minter expects that the biotechnology company will earn $4.03 per share for the quarter. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen’s Q4 2025 earnings at $3.58 EPS, Q1 2026 earnings at $4.60 EPS, Q2 2026 earnings at $4.60 EPS, Q3 2026 earnings at $3.35 EPS, Q4 2026 earnings at $3.38 EPS, FY2027 earnings at $17.07 EPS, FY2028 earnings at $18.06 EPS and FY2029 earnings at $19.25 EPS.

Biogen (NASDAQ:BIIB) last issued its earnings results on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing analysts’ consensus estimates of $3.26 by ($0.24). The company had revenue of $2.43 billion during the quarter, compared to the consensus estimate of $2.25 billion. Biogen had a return on equity of 14.03% and a net margin of 15.07%. Biogen’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.67 earnings per share.

A number of other brokerages also recently commented on BIIB. Royal Bank Of Canada set a $213.00 target price on shares of Biogen and gave the stock an “outperform” rating in a research note on Wednesday, June 25th. Oppenheimer set a $205.00 price target on shares of Biogen in a research report on Friday, May 2nd. Mizuho lowered their price target on shares of Biogen from $207.00 to $169.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Morgan Stanley lowered their price target on shares of Biogen from $157.00 to $152.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. Finally, Argus cut shares of Biogen from a “buy” rating to a “hold” rating in a research report on Friday, April 4th. Twenty analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $188.48.

Biogen Price Performance

Shares of BIIB stock opened at $128.69 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.44 and a quick ratio of 1.01. The company has a market capitalization of $18.86 billion, a P/E ratio of 12.70, a P/E/G ratio of 1.03 and a beta of 0.14. The company’s 50-day simple moving average is $129.04 and its two-hundred day simple moving average is $133.50. Biogen has a one year low of $110.04 and a one year high of $236.48.

Insider Transactions at Biogen

In other Biogen news, insider Rachid Izzar sold 2,223 shares of the company’s stock in a transaction that occurred on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total transaction of $300,105.00. Following the transaction, the insider owned 6,330 shares in the company, valued at approximately $854,550. This represents a 25.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.18% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Lee Danner & Bass Inc. acquired a new position in Biogen during the 4th quarter valued at approximately $25,000. Opal Wealth Advisors LLC acquired a new stake in shares of Biogen in the first quarter worth $26,000. Vision Financial Markets LLC acquired a new stake in shares of Biogen in the first quarter worth $27,000. Greykasell Wealth Strategies Inc. acquired a new stake in shares of Biogen in the first quarter worth $27,000. Finally, Colonial Trust Co SC increased its stake in shares of Biogen by 9,300.0% in the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 186 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.